Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$78.6MCash on Hand
10.5mo Cash Runway
Follow ABOS by emailGet an email when ABOS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ABOS, unsubscribe in one click. Privacy
📣 What ABOS Says Is Next
coming weeks · “Acumen expects to receive and analyze additional data from ALTITUDE-AD in the coming weeks, including fluid biomarker and additional imaging data, but does not expect these data to change the efficacy conclusions of the trial.”
Company press release, Oct 30, 2026 · SEC filing
in November 2026 · “The Company expects to report topline results from ALTITUDE-AD in November 2026.”
Company press release, Oct 26, 2026 · SEC filing
in November 2026 · Sabirnetug: ““In the third quarter, we continued readying for the readout from our ALTITUDE-AD Phase 2 study investigating the efficacy, safety and tolerability of sabirnetug for the treatment of early AD, and today I’m pleased to announce that we expect to report topline results in November 2026.”
Company press release, Oct 26, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 5, 2026 ·
Financing Acumen terminated its $50.0 million K2 HealthVentures loan after paying off $23.3 million in full, using cash on hand. The payoff included $1.6 million in final payment fees. Lender liens were released. Form 8-K · SEC filing
Oct 30, 2026 ·
Clinical trial Acumen's Phase 2 ALTITUDE-AD trial of sabirnetug did not meet its primary endpoint on the iADRS at 18 months at either dose; the company will cease development and explore strategic options and cash conservation. Form 8-K · SEC filing · Press release
Oct 26, 2026 ·
Earnings Reported Q3 2026 results: cash, equivalents and marketable securities of $78.6 million as of Sept. 30, 2026, expected to fund operations into early 2027. Topline Phase 2 ALTITUDE-AD results for sabirnetug expected in November 2026. Form 8-K · SEC filing · Press release
Oct 26, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 26, 2026 ·
Financing Acumen Pharmaceuticals filed a shelf registration statement on Form S-3 for up to $500,000,000 of common stock, preferred stock, debt securities and warrants, to be sold from time to time. Specific terms will be set in future prospectus supplements. Form S-3 · SEC filing
Sep 16, 2026 ·
Acumen will hold a live-webcast Investor Day on September 16, 2026, at 10:00 a.m. ET, with the slide presentation furnished as Exhibit 99.1. The filing states Phase 2 ALTITUDE-AD topline results are expected late 2026. Form 8-K · SEC filing · Press release
Aug 12, 2026 ·
Earnings Reported Q2 2026 results: cash, equivalents and marketable securities of $110.2 million as of June 30, 2026, expected to fund operations into early 2027. R&D expenses fell to $27.8 million from $37.1 million, and net loss was $32.7 million versus $41.0 million. Form 8-K · SEC filing · Press release
Aug 12, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Oct 2026 · Phase 2 · Active Trial · A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD) Registry date passed, readout not confirmed
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
ABOS holds $78.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $22.4M/quarter from operations,
an estimated runway of 10.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:77 · High
Cash runway 10 months +30
ATM program on file since Nov 2025 +15
Shelf registration (S-3, Oct 2026) +10
Going-concern doubt in the latest 10-Q +15Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.10-Q, Oct 2026
Share count +19% in a year +7
Recent financing filings on SEC EDGAR:
Oct 26, 2026 · Shelf registration, up to $500M · S-3
Share count 72,327,320 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full ABOS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ABOS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.